Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob P van Vloten

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Molecular Therapy. Methods & Clinical Development|August 17, 2018
Use of Precision-Cut Lung Slices as an <i>Ex Vivo</i> Tool for Evaluating Viruses and Viral Vectors for Gene and Oncolytic TherapyMaría C Rosales Gerpe, Jacob P van Vloten, Lisa A Santry, et al.
The Journal of General Virology|August 22, 2024
Investigating the effect of reduced temperatures on the efficacy of rhabdovirus-based viral vector platformsJulia E Kakish, Yeganeh Mehrani, Arthane Kodeeswaran, et al.
Scientific Reports|August 18, 2017
Enhancing Immune Responses to Cancer Vaccines Using Multi-Site InjectionsRobert C Mould, Amanda W K AuYeung, Jacob P van Vloten, et al.
Frontiers in Immunology|December 5, 2022
Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapiesJessica A Minott, Jacob P van Vloten, Jacob G E Yates, et al.
Frontiers in Microbiology|February 8, 2024
Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancerLisa A Santry, Jacob P van Vloten, Amanda W K AuYeung, et al.
Cytokine & Growth Factor Reviews|September 7, 2020
Tumour vasculature: Friend or foe of oncolytic viruses?Lisa A Santry, Jacob P van Vloten, Jason P Knapp, et al.
Cancers|December 24, 2021
Using a Prime-Boost Vaccination Strategy That Proved Effective for High Resolution Epitope Mapping to Characterize the Elusive Immunogenicity of SurvivinRobert C Mould, Jacob P van Vloten, Amanda W K AuYeung, et al.
Human Gene Therapy|February 1, 2020
Optimized Pre-Clinical Grade Production of Two Novel Lentiviral Vector Pseudotypes for Lung Gene DeliveryMaría C Rosales Gerpe, Laura P van Lieshout, Jakob M Domm, et al.
Molecular Therapy Oncolytics|December 11, 2023
Kinetic analysis of oncolytic OrfV-induced innate and adaptive immune responses in a murine model of late-stage ovarian cancerJessica A Minott, Jacob P van Vloten, Jake G E Yates, et al.
Molecular Therapy Oncolytics|February 22, 2021
Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer modelsThomas M McAusland, Jacob P van Vloten, Lisa A Santry, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Molecular Therapy. Methods & Clinical Development|August 17, 2018
Use of Precision-Cut Lung Slices as an <i>Ex Vivo</i> Tool for Evaluating Viruses and Viral Vectors for Gene and Oncolytic TherapyMaría C Rosales Gerpe, Jacob P van Vloten, Lisa A Santry, et al.
The Journal of General Virology|August 22, 2024
Investigating the effect of reduced temperatures on the efficacy of rhabdovirus-based viral vector platformsJulia E Kakish, Yeganeh Mehrani, Arthane Kodeeswaran, et al.
Scientific Reports|August 18, 2017
Enhancing Immune Responses to Cancer Vaccines Using Multi-Site InjectionsRobert C Mould, Amanda W K AuYeung, Jacob P van Vloten, et al.
Frontiers in Immunology|December 5, 2022
Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapiesJessica A Minott, Jacob P van Vloten, Jacob G E Yates, et al.
Frontiers in Microbiology|February 8, 2024
Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancerLisa A Santry, Jacob P van Vloten, Amanda W K AuYeung, et al.
Cytokine & Growth Factor Reviews|September 7, 2020
Tumour vasculature: Friend or foe of oncolytic viruses?Lisa A Santry, Jacob P van Vloten, Jason P Knapp, et al.
Cancers|December 24, 2021
Using a Prime-Boost Vaccination Strategy That Proved Effective for High Resolution Epitope Mapping to Characterize the Elusive Immunogenicity of SurvivinRobert C Mould, Jacob P van Vloten, Amanda W K AuYeung, et al.
Human Gene Therapy|February 1, 2020
Optimized Pre-Clinical Grade Production of Two Novel Lentiviral Vector Pseudotypes for Lung Gene DeliveryMaría C Rosales Gerpe, Laura P van Lieshout, Jakob M Domm, et al.
Molecular Therapy Oncolytics|December 11, 2023
Kinetic analysis of oncolytic OrfV-induced innate and adaptive immune responses in a murine model of late-stage ovarian cancerJessica A Minott, Jacob P van Vloten, Jake G E Yates, et al.
Molecular Therapy Oncolytics|February 22, 2021
Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer modelsThomas M McAusland, Jacob P van Vloten, Lisa A Santry, et al.
Pageof 3